JAK-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis

Mostrar otras versiones (1)

BACKGROUND: The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 17 million. Novel therapies are urgently needed. Janus kinase-inhibitors and Type I interferons have emerged as potential antiviral candidates for C...

Descripción completa

Detalles Bibliográficos
Autores principales: Walz, Lucas, Cohen, Avi J., Rebaza, Andre P., Vanchieri, James, Slade, Martin D., Dela Cruz, Charles S., Sharma, Lokesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457585/
https://www.ncbi.nlm.nih.gov/pubmed/32869016
http://dx.doi.org/10.21203/rs.3.rs-64782/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457585/
https://www.ncbi.nlm.nih.gov/pubmed/32869016
http://dx.doi.org/10.21203/rs.3.rs-64782/v1

Ejemplares similares